Riskpilot← Back to searchSign inGet full accessBIOMOLEX AS
ASActiveOrg 983453430Melkeveien 39B, 0779 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20011 employeesbiomolex.com
Revenue 2024
NOK 301K
-88% vs 2023
EBITDA margin
70.3%
-89% vs 2023
Equity ratio
-25462.7%
Financial strength
Net profit 2024
NOK -402K
-149% vs 2023
| Revenue | NOK 301K | -88% |
| EBITDA | NOK 212K | -89% |
| Net profit | NOK -402K | -149% |
| Total assets | NOK 961 | -100% |
| Equity | NOK -245K | -256% |
| Employees | 1 | — |
Legal name
BIOMOLEX AS
Org number
983453430
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20. juni 2001
Share capital
NOK 831 834
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Kjøpe, selge, utvikle og kommersialisere metoder, tjenester og produkter innenfor bioteknologi.
Address
Melkeveien 39B, 0779 Oslo
Website
biomolex.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 660 | 4 223 | 5 615 | 5 638 | 4 560 | 0 | 3 759 | 2 334 | 5 076 | 6 099 | 5 419 | 4 434 | 2 757 | 2 264 | 1 332 | 2 515 | 301 |
| Staff expenses | −1 573 | −1 662 | −1 614 | −2 100 | −1 148 | −0 | −1 465 | −2 626 | 509 | 495 | −28 | −143 | −806 | −628 | −566 | −219 | −0 |
| EBITDA | −351 | −871 | 288 | −37 | −343 | 0 | 1 279 | −1 574 | 4 074 | 4 655 | 4 491 | 3 396 | 1 339 | 1 260 | 20 | 1 981 | 212 |
| Depreciation & amort. | −45 | −58 | −58 | −58 | −26 | −0 | −4 | −4 | −1 064 | −2 178 | −2 974 | −3 692 | −3 975 | −3 080 | −1 963 | −1 166 | −613 |
| EBIT | −396 | −928 | 231 | −95 | −369 | 0 | 1 275 | −1 579 | 3 009 | 2 477 | 1 517 | −297 | −2 635 | −1 820 | −1 943 | 815 | −401 |
| Net financials | 39 | 22 | 24 | 33 | 23 | 0 | 10 | 2 | 18 | 3 | −46 | −6 | −18 | −2 | −5 | −3 | −0 |
| Profit before tax | −357 | −907 | 255 | −61 | −345 | 0 | 1 285 | −1 577 | 3 027 | 2 480 | 1 471 | −302 | −2 654 | −1 822 | −1 947 | 812 | −402 |
| Tax | 1 800 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 157 | −907 | 255 | −61 | −345 | 0 | 1 285 | −1 577 | 3 027 | 2 480 | 1 471 | −302 | −2 654 | −1 822 | −1 947 | 812 | −402 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 835 | 2 946 | 3 273 | 3 621 | 2 241 | — | 2 947 | 1 968 | 7 047 | 10 402 | 10 915 | 10 506 | 6 808 | 4 277 | 1 897 | 618 | 1 |
| Equity | 814 | −93 | 483 | 421 | 76 | — | 669 | −907 | 2 120 | 4 600 | 6 071 | 5 768 | 3 115 | 1 292 | −655 | 157 | −245 |
| Long-term debt | 312 | 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 796 | 0 | 0 |
| Short-term debt | 1 709 | 2 883 | 2 790 | 3 200 | 2 165 | 0 | 2 278 | 2 875 | 4 079 | 4 273 | 3 113 | 3 057 | 2 530 | 2 270 | 423 | 351 | 246 |
| Total debt | 2 021 | 3 039 | 2 790 | 3 200 | 2 165 | 0 | 2 278 | 2 875 | 4 079 | 4 273 | 3 113 | 3 057 | 2 530 | 2 270 | 2 219 | 351 | 246 |
EBITDA margin
70.3%
This company
15.8%
Market median
+345% vs market
20082024
Equity ratio
-25462.7%
This company
38.2%
Market median
-66756% vs market
20082024
Return on equity
-40153400.0%
This company
18.4%
Market median
-218225100% vs market
20082024
Net profit margin
-133.4%
This company
8.1%
Market median
-1747% vs market
20082024
Asset turnover
313.27×
This company
1.12×
Market median
+27871% vs market
20082024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HH Chief Executive Officer | Chief Executive Officer | 2002 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Radforsk Investeringsstiftelse | Company | 20.3% | 20.3% | 2022 |
Inventron As | Company | 15.1% | 15.1% | 2022 |
Cerolu As | Company | 11.3% | 11.3% | 2022 |
Integrated Detector Electronics As | Company | 7.5% | 7.5% | 2022 |
Skilling Systemer As | Company | 7.5% | 7.5% | 2022 |
Sveinja Invest As | Company | 7.5% | 7.5% | 2022 |
Inven2 As | Company | 3.3% | 3.3% | 2022 |
| Individual | 3.1% | 3.1% | 2022 | |
Ja Consult As | Company | 2.6% | 2.6% | 2022 |
| Individual | 2.4% | 2.4% | 2022 | |
| Individual | 2.4% | 2.4% | 2022 | |
| Individual | 1.6% | 1.6% | 2022 | |
Kimen As | Company | 1.6% | 1.6% | 2022 |
Gillesen Overseas & Co As | Company | 1.4% | 1.4% | 2022 |
Oslotech As | Company | 1.3% | 1.3% | 2022 |
| Individual | 1.2% | 1.2% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Inventron As
BIOMOLEX AS Board members of BIOMOLEX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Håvard Hildeng Hauge | Chief Executive Officer | 0 companies |
| Grete Vigen Rode | Board of Directors | 0 companies |
| Jonas Einarsson | Board of Directors | 0 companies |